Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 1081 drug-target rows in SSL view, for TSG = PMS2.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib PMS2 PARP1 1
sunitinib PMS2 KDR 5
gemcitabine PMS2 RRM1 5
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PMS2 ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PMS2 EPHB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PMS2 CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PMS2 KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PMS2 CDK6 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus PMS2 MTOR 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PMS2 CTLA4 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PMS2 ABL1 3
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PMS2 KDR 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PMS2 ABL1 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PMS2 KDR 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab PMS2 RRM1 3
cabozantinib PMS2 KDR 5
everolimus PMS2 MTOR 5
nintedanib PMS2 KDR 5
palbociclib PMS2 CDK4 5
palbociclib PMS2 CDK6 5
regorafenib PMS2 ABL1 5
regorafenib PMS2 KDR 5
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin PMS2 RRM1 2
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis PMS2 PDPK1 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine PMS2 RRM1 2
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine PMS2 KDR 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PMS2 ABL1 2
antineoplastic vaccine, sargramostim, pembrolizumab PMS2 CSF2RB 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan PMS2 KDR 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine PMS2 RRM1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 PMS2 KDR 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PMS2 ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PMS2 EPHB4 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib PMS2 CDK4 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib PMS2 CDK6 2
biospecimen collection, computed tomography, echocardiography, ipilimumab, magnetic resonance imaging, nivolumab PMS2 CTLA4 2
bms-986207, nivolumab, ipilimumab PMS2 CTLA4 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab PMS2 RRM1 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab PMS2 CDK4 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab PMS2 CDK6 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PMS2 JAK2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PMS2 KDR 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib PMS2 JAK2 2
ipilimumab PMS2 CTLA4 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine PMS2 RRM1 2
lenvatinib, pembrolizumab PMS2 KDR 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate PMS2 KDR 2
ly3022855, durvalumab, tremelimumab PMS2 CTLA4 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab PMS2 RRM1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed PMS2 RRM1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PMS2 KDR 2
motexafin gadolinium, radiation therapy PMS2 RRM2 2
nintedanib, pembrolizumab PMS2 KDR 2
nivolumab, ipilimumab PMS2 CTLA4 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu PMS2 RRM1 2
paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5fu) + leucovorin (calcium folinate/folinic acid), durvalumab, tremelimumab, nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5fu) PMS2 CTLA4 2
pembrolizumab, belzutifan, lenvatinib PMS2 KDR 2
pembrolizumab, lenvatinib PMS2 KDR 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu PMS2 KDR 2
ramucirumab PMS2 KDR 2
regorafenib, laboratory biomarker analysis PMS2 ABL1 2
regorafenib, laboratory biomarker analysis PMS2 KDR 2
selumetinib, medi4736, tremelimumab PMS2 CTLA4 2
stereotactic body radiotherapy, ipilimumab, nivolumab, pembrolizumab or atezolizumab PMS2 CTLA4 2
trabectedin, ipilimumab, nivolumab PMS2 CTLA4 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy PMS2 KDR 2
abemaciclib PMS2 CDK4 5
abemaciclib PMS2 CDK6 5
axitinib PMS2 KDR 5
bosutinib PMS2 ABL1 5
entrectinib PMS2 JAK2 5
pazopanib PMS2 KDR 5
ponatinib PMS2 ABL1 5
ribociclib PMS2 CDK4 5
ribociclib PMS2 CDK6 5
sorafenib PMS2 KDR 5
tadalafil PMS2 PDE5A 5
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography PMS2 PARP3 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide PMS2 RRM2 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) PMS2 KDR 1
7-hydroxystaurosporine, fluorouracil PMS2 PDPK1 1
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis PMS2 PDPK1 1
9-ing-41, retifanlimab, gemcitabine, abraxane PMS2 RRM1 1
abemaciclib, abemaciclib PMS2 CDK4 1
abemaciclib, abemaciclib PMS2 CDK6 1
abemaciclib, bevacizumab PMS2 CDK4 1
abemaciclib, bevacizumab PMS2 CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf PMS2 CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf PMS2 CDK6 1
abemaciclib, ly3023414, gemcitabine, capecitabine PMS2 RRM1 1
abemaciclib, ly3023414, gemcitabine, capecitabine PMS2 CDK4 1
abemaciclib, ly3023414, gemcitabine, capecitabine PMS2 CDK6 1
abemaciclib, ly3214996 PMS2 CDK4 1
abemaciclib, ly3214996 PMS2 CDK6 1
abemaciclib, surgery PMS2 CDK4 1
abemaciclib, surgery PMS2 CDK6 1
abraxane (nab-paclitaxel), gemcitabine PMS2 RRM1 1
adct-601, gemcitabine PMS2 RRM1 1
aee788, everolimus PMS2 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PMS2 PARP3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PMS2 ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PMS2 EPHB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PMS2 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PMS2 CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PMS2 CDK6 1
ag-013736, gemcitabine, gemcitabine, placebo PMS2 RRM1 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel PMS2 RRM1 1
agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel PMS2 KDR 1
ags-1c4d4, gemcitabine PMS2 RRM1 1
ak104, ak104, gemcitabine, nab-paclitaxel PMS2 RRM1 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine PMS2 RRM1 1
albumin-bound paclitaxel (abi-007), gemcitabine PMS2 RRM1 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim PMS2 IL2RB 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim PMS2 CSF2RB 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation PMS2 IL2RB 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation PMS2 CSF2RB 1
aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy PMS2 IL2RB 1
aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy PMS2 CSF2RB 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes PMS2 IL2RB 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes PMS2 RRM1 1
aldesleukin, muromonab-cd3, therapeutic tumor infiltrating lymphocytes, conventional surgery PMS2 IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery PMS2 IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, zoledronic acid PMS2 IL2RB 1
alendronate, etidronate, ibandronate, risedronate, raloxifene PMS2 ESR2 1
alisertib, gemcitabine PMS2 RRM1 1
allogeneic tumor cell vaccine, recombinant interferon alfa, sargramostim, cyclophosphamide PMS2 CSF2RB 1
alpelisib, everolimus, exemestane PMS2 MTOR 1
alvocidib, docetaxel PMS2 CDK4 1
alvocidib, docetaxel PMS2 CDK2 1
alvocidib, docetaxel PMS2 CDK6 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis PMS2 CDK4 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis PMS2 CDK2 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis PMS2 CDK6 1
alvocidib, paclitaxel PMS2 CDK4 1
alvocidib, paclitaxel PMS2 CDK2 1
alvocidib, paclitaxel PMS2 CDK6 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox PMS2 RRM1 1
amg 479, placebo, amg 479, gemcitabine PMS2 RRM1 1
anakinra PMS2 IL1R1 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel PMS2 RRM1 1
anetumab ravtansine, biopsy, biospecimen collection, gemcitabine hydrochloride, ipilimumab, nivolumab PMS2 CTLA4 1
anti-sema4d monoclonal antibody vx15/2503, ipilimumab, nivolumab, surgery PMS2 CTLA4 1
apg-1387 for injection, gemcitabine, nab paclitaxel PMS2 RRM1 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib PMS2 MTOR 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib PMS2 CDK4 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib PMS2 CDK6 1
apx005m, nivolumab, nab-paclitaxel, gemcitabine PMS2 RRM1 1
arq 197, gemcitabine PMS2 RRM1 1
arsenic trioxide PMS2 CCND1 1
arsenic trioxide, radiation therapy PMS2 CCND1 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy PMS2 CCND1 1
ascorbate, nab paclitaxel, gemcitabine PMS2 RRM1 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine PMS2 RRM1 1
atezolizumab, cabozantinib PMS2 KDR 1
atezolizumab, tivozanib PMS2 KDR 1
atra, gemcitabine, nab-paclitaxel PMS2 RRM1 1
autologous mesothelin-specific tcr-t cells, cyclophosphamide, fludarabine, bendamustine PMS2 RRM1 1
autologous tumor cell vaccine, sargramostim, tumor-draining lymph node lymphocyte therapy, cyclophosphamide, conventional surgery PMS2 CSF2RB 1
avastin (bevacizumab), gemcitabine, radiation therapy PMS2 RRM1 1
axitinib, avelumab PMS2 KDR 1
axitinib, axitinib plus lomustine PMS2 KDR 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab PMS2 DNMT1 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab PMS2 RRM1 1
azd0171, durvalumab, gemcitabine, nab-paclitaxel PMS2 RRM1 1
azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine PMS2 RRM1 1
azd1775, gemcitabine, nab-paclitaxel PMS2 RRM1 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus PMS2 MTOR 1
bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 PMS2 RRM1 1
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil PMS2 KDR 1
bendamustine, biopsy, biospecimen collection, computed tomography, cyclophosphamide, echocardiography, fludarabine, leukapheresis, magnetic resonance imaging, multigated acquisition scan, positron emission tomography, t-cell receptor-engineered t-cells PMS2 RRM1 1
bethanechol PMS2 CHRM5 1
bethanechol, gemcitabine, nab-paclitaxel PMS2 CHRM5 1
bethanechol, gemcitabine, nab-paclitaxel PMS2 RRM1 1
bevacizumab, cediranib, cediranib maleate, olaparib PMS2 PARP3 1
bevacizumab, cediranib, cediranib maleate, olaparib PMS2 KDR 1
bevacizumab, dasatinib, placebo PMS2 ABL1 1
bevacizumab, dasatinib, placebo PMS2 EPHB4 1
bevacizumab, erlotinib, gemcitabine PMS2 RRM1 1
bevacizumab, everolimus, octreotide acetate PMS2 MTOR 1
bevacizumab, temsirolimus PMS2 MTOR 1
bi 765883, gemcitabine, nab-paclitaxel PMS2 RRM1 1
biopsy, biospecimen collection, cisplatin, computed tomography, gemcitabine, gemcitabine hydrochloride, magnetic resonance imaging, veliparib PMS2 RRM1 1
biopsy, biospecimen collection, cisplatin, computed tomography, gemcitabine, magnetic resonance imaging, nab-paclitaxel, pancreatic surgical procedure PMS2 RRM1 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib PMS2 KDR 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging PMS2 KDR 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib PMS2 PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab PMS2 PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, palbociclib PMS2 CDK4 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, palbociclib PMS2 CDK6 1
biopsy, biospecimen collection, diagnostic imaging, elimusertib, gemcitabine PMS2 RRM1 1
biospecimen collection, cholestyramine, computed tomography, diagnostic imaging, gemcitabine, leflunomide, magnetic resonance imaging PMS2 RRM1 1
biospecimen collection, computed tomography, magnetic resonance imaging, nivolumab, paclitaxel, questionnaire administration, ramucirumab PMS2 KDR 1
biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration PMS2 PARP3 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography PMS2 KDR 1
blu-222, carboplatin, ribociclib, fulvestrant PMS2 CDK4 1
blu-222, carboplatin, ribociclib, fulvestrant PMS2 CDK6 1
bms-813160, nivolumab, gemcitabine, nab-paclitaxel, biopsy, peripheral blood PMS2 RRM1 1
botensilimab, balstilimab, chloroquine phosphate, celecoxib PMS2 PDPK1 1
botensilimab, gemcitabine, nab-paclitaxel PMS2 RRM1 1
bryostatin 1, paclitaxel PMS2 CCND1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.